Evidence map›Paper›PMID 35423416›Full record

ArticleRSC advances2021

Anticancer potential of nitric oxide (NO) in neuroblastoma treatment.

Jenna L Gordon, Kristin J Hinsen, Melissa M Reynolds, Tyler A Smith, Haley O Tucker, Mark A Brown

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in RSC advances, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.1field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Jenna L GordonDepartment of Chemistry, Colorado State University Fort Collins CO 80521 USA jenna.short@colostate.edu.ORCID https://orcid.org/0000-0003-1346-8879
Kristin J HinsenDepartment of Biomedical Sciences, Colorado State University Fort Collins CO 80521 USA khinsen@rams.colostate.edu.
Melissa M ReynoldsDepartment of Chemistry, School of Biomedical Engineering, Department of Chemical and Biological Engineering, Colorado State University, Campus Delivery 1872 Fort Collins CO 80523 USA Melissa.reynolds@colostate.edu.ORCID https://orcid.org/0000-0002-1836-7324
Tyler A SmithDepartment of Neuroscience, University of Texas Austin 2500 Speedway Austin TX 78712 USA tylersmith128@utexas.edu.
Haley O TuckerDepartment of Molecular Genetics, Institute for Cellular and Molecular Biology, University of Texas Austin Austin TX 78712 USA haleytucker@austin.utexas.edu.
Mark A BrownDepartment of Clinical Sciences, Colorado State University Fort Collins CO 80523 USA mark.brown@colostate.edu.
Colorado State University · USInstitut de Biologie Moléculaire et Cellulaire · FRThe University of Texas at Austin · US

Funding

MAR MEDIATED GENETIC SWITCH FOR IGH ENHANCER CONTROLR01CA031534 · NCI · UNIVERSITY OF TEXAS SW MED CTR/DALLAS · PI TUCKER, HALEY O · 1985 to 2012
$2.9M
NCI NIH HHS R01 CA031534
6 · The paper itself

Abstract

The most common extracranial solid tumor in childhood, paediatric neuroblastoma, is frequently diagnosed at advanced stages and identified as high risk. High risk neuroblastoma is aggressive and unpredictable, resulting in poor prognosis and only ∼40% five-year survival rates. Herein, nitric oxide (NO) delivered

Identifiers

PMID35423416
PMCPMC8695301
OpenAlexW3133670520

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.